NCT04420741View on ClinicalTrials.gov

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

February 23, 2021

Study Completion Date

April 23, 2021

Conditions
COVID-19Respiratory Failure
Interventions
DRUG

Iloprost

Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min

DRUG

Isotonic saline

Continuously infusion for 72 hours at 3 ml/hours

Trial Locations (5)

Unknown

Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen

Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen

Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev

Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød

Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital, Hvidovre

All Listed Sponsors
lead

Pär Johansson

OTHER

NCT04420741 - Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure | Biotech Hunter | Biotech Hunter